{
    "symbol": "SGEN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-04-28 18:51:09",
    "content": " Today's conference call will include forward-looking statements regarding future or anticipated events and results, including the company's 2022 financial outlook, anticipated product sales, revenues, costs and expenses, future developments related to legal matters and potential clinical and regulatory milestones, including data readouts, regulatory submissions and potential marketing and reimbursement approvals. EV-103 cohort K data, which are anticipated in the second half of this year, along with other data from the EV-103 trial could potentially support accelerated approval in the US for patients with first-line metastatic urothelial cancer next year. And, in fact, we're really proud that we have a HER2 franchise with our small molecule and our antibody, targeting the inside of the cell and the HER2 -- through the HER2 tyrosine kinase, is an important mechanism targeting outside of the cell through an ADC, through an antibody that then delivers a potency to be inside of the cell, we think could come at it and really attack the cancer cell and do well by patients."
}